Comparing tegoprazan and PPIs for treating H. pylori infection
Efficacy and Tolerability of 14-Day Tegoprazan-based Triple Therapy for Eradication of Helicobacter Pylori Eradication: A Retrospective Study
This study is testing if tegoprazan, a new type of acid blocker, works better than traditional medications for treating H. pylori infections in patients who can have a gastroscopy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | Soonchunhyang University Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06682533 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of tegoprazan, a potassium-competitive acid blocker, compared to traditional proton pump inhibitors (PPIs) in eradicating Helicobacter pylori. The study focuses on assessing the eradication success rate and treatment compliance when using tegoprazan in combination with bismuth for first-line H. pylori treatment. The research is based on previous findings that suggest P-CABs like tegoprazan may improve patient compliance due to their dosing flexibility. The study will involve patients who can undergo gastroscopy and H. pylori testing.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 20 to 80 who require treatment for H. pylori infection and can undergo necessary diagnostic procedures.
Not a fit: Patients with severe systemic diseases, advanced chronic liver disease, or those who have previously undergone H. pylori eradication may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective and patient-friendly treatment option for H. pylori infection.
How similar studies have performed: Previous studies have shown success with similar P-CAB approaches, indicating a promising avenue for H. pylori treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Gastroscopy can be performed * H. pylori test and pathological analysis can be performed Exclusion Criteria: * Age \< 20 or \> 80 years * Anemia (serum hemoglobin level \< 10 g/dL) * Severe systemic disease * Advanced chronic liver disease * Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics * History of H. pylori eradication * Drug allergy to antibiotics * History of gastric surgery * Recent history of upper gastrointestinal bleeding
Where this trial is running
Seoul
- Digestive Disease Center, Soonchunhyang University Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Jun-Hyung Cho, M.D. — Soonchunhyang University Hospital
- Study coordinator: Jun-Hyung Cho
- Email: chojhmd@naver.com
- Phone: +82-2-709-9202
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.